The biology of the combretastatins as tumour vascular targeting agents
Open Access
- 1 February 2002
- journal article
- review article
- Published by Wiley in International Journal of Experimental Pathology
- Vol. 83 (1), 21-38
- https://doi.org/10.1046/j.1365-2613.2002.00211.x
Abstract
The tumour vasculature is an attractive target for therapy. Combretastatin A-4 (CA-4) and A-1 (CA-1) are tubulin binding agents, structurally related to colchicine, which induce vascular-mediated tumour necrosis in animal models. CA-1 and CA-4 were isolated from the African bush willow, Combretum caffrum, and several synthetic analogues are also now available, such as the Aventis Pharma compound, AVE8062. More soluble, phosphated, forms of CA-4 (CA-4-P) and CA-1 (CA-1-P) are commonly used for in vitro and in vivo studies. These are cleaved to the natural forms by endogenous phosphatases and are taken up into cells. The lead compound, CA-4-P, is currently in clinical trial as a tumour vascular targeting agent. In animal models, CA-4-P causes a prolonged and extensive shut-down of blood flow in established tumour blood vessels, with much less effect in normal tissues. This paper reviews the current understanding of the mechanism of action of the combretastatins and their therapeutic potential.Keywords
This publication has 114 references indexed in Scilit:
- Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor TherapyJapanese Journal of Cancer Research, 1999
- Tumor Vascular Targeting Using a Tumor-Tissue Endothelium-Specific Monoclonal Antibody as an Effective Strategy for Cancer ChemotherapyBiochemical and Biophysical Research Communications, 1999
- Clinical applications of TNF-α in cancerCurrent Opinion in Immunology, 1998
- Vinca alkaloids: Anti-vascular effects in a murine tumourEuropean Journal of Cancer, 1993
- The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factorsCell, 1992
- Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanismEuropean Journal of Cancer and Clinical Oncology, 1991
- Differential cytotoxicity of Combretastatins A1 and A4 in two daunorubicin-resistant P388 cell linesCancer Chemotherapy and Pharmacology, 1990
- Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumour actionEuropean Journal of Cancer and Clinical Oncology, 1989
- Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4Cellular and Molecular Life Sciences, 1989
- Vascular occlusion and tumour cell deathEuropean Journal of Cancer and Clinical Oncology, 1983